TP53 and neoplasm: Reports indicate that the loss of tumor suppressor functions like TP53 and RB1 promotes the transition of AR-dependent luminal epithelial cells to AR-independent basal-like cells, and EZH2 inhibitors have been found to reverse this lineage transition and to restore sensitivity to androgen deprivation therapy8.